Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction

Julie K K Vishram-Nielsen, Daniela Tomasoni, Finn Gustafsson, Marco Metra*

*Corresponding author af dette arbejde

Abstract

The introduction of multiple new pharmacological agents over the past three decades in the field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of mortality and hospitalizations, and consequently the prevalence of HFrEF has increased, and up to 10% of patients progress to more advanced stages, characterized by high rates of mortality, hospitalizations, and poor quality of life. Advanced HFrEF patients often show persistent or progressive signs of severe HF symptoms corresponding to New York Heart Association class III or IV despite being on optimal medical, surgical, and device therapies. However, a subpopulation of patients with advanced HF, those with the most advanced stages of disease, were often insufficiently represented in the major trials demonstrating efficacy and tolerability of the drugs used in HFrEF due to exclusion criteria such as low BP and kidney dysfunction. Consequently, the results of many landmark trials cannot necessarily be transferred to patients with the most advanced stages of HFrEF. Thus, the efficacy and tolerability of guideline-directed medical therapies in patients with the most advanced stages of HFrEF often remain unsettled, and this knowledge is of crucial importance in the planning and timing of consideration for referral for advanced therapies. This review discusses the evidence regarding the use of contemporary drugs in the advanced HFrEF population, covering components such as guideline HFrEF drugs, diuretics, inotropes, and the use of HFrEF drugs in LVAD recipients, and provides suggestions on how to manage guideline-directed therapy in this patient group.

OriginalsprogEngelsk
TidsskriftDrugs
Vol/bind82
Udgave nummer4
Sider (fra-til)375-405
Antal sider31
ISSN0012-6667
DOI
StatusUdgivet - mar. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction'. Sammen danner de et unikt fingeraftryk.

Citationsformater